Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of AC-170 0.24% in Healthy Adults and Pediatric Subjects with Atopic History
NCT02132169Phase 3Completed
- Sponsor
- Aciex Therapeutics
- Start
- May 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cetirizine in allergic conjunctivitis (AC), sponsored by Aciex Therapeutics. Started May 2014; status: completed.
02
Drugs
cetirizine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT02132169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02132169.